An observational study in Pain (Visceral, Somatic, or Neuropathic), Hip Arthroplasty Replacement and Knee Arthroplasty, Total, sponsored by Rigshospitalet, Denmark. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Rigshospitalet, Denmark · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Pain by Rigshospitalet, Denmark — 2 open to participants now, 2 under way, none of them phase 3. Pain · Rigshospitalet, Denmark.
Among the 28 studies in Pain by Rigshospitalet, Denmark, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2025, is one of 11 observational ones, and was the 27th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →2 of the 28 studies in Pain by Rigshospitalet, Denmark are open now, in 1 country. Recruiting first, the newest first:
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 1,253 observational studies indexed under Pain.
Median enrollment 58 across the 17 interventional studies, 82 across the 11 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rigshospitalet, Denmark is the lead sponsor of 1,004 studies on the registry; 173 are open to participants now.
2 of the studies in Pain by Rigshospitalet, Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07110324Rigshospitalet, DenmarkCharacteristics of Persistent Pain Composition Following Total Hip or Knee Arthroplasty: a Descriptive Study | 2026-12-01 |
| NCT06351046Rigshospitalet, DenmarkPreventive Interventions for Chronic Pain Worsening | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Pain by Rigshospitalet, Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Despite high success rates of hip and knee arthroplasty, up to 20% of patients report moderate-to-severe pain (NRS > 3) persisting beyond the expected healing period. This investigator-initiated, descriptive cohort study will re-invite approximately 100 consenting patients with persistent postoperative pain-identified from a pool of \~7 000 respondents-to complete standardized assessments of neuropathic (DN4), nociplastic (IASP criteria + Fibromyalgia Survey Questionnaire) and nociceptive (KOOS/HOOS pain domains) pain. Primary outcomes are the prevalence of potential nociplastic pain and the proportion experiencing significant pain in two or more mechanistic categories. Secondary analyses will compare baseline vs. re-evaluated DN4 scores, FSQ and KOOS/HOOS distributions, and examine differences between patients with and without possible neuropathic pain. Findings will inform targeted pre- and postoperative pain management strategies.
Introduction Background: Knee and hip arthroplasties are primarily performed due to degenerative changes that typically result in pain, functional impairment, and a subsequent decline in quality of life [1]. Arthroplasty represents the definitive intervention, involving the removal of the degenerated, pain-inducing joint components and their replacement with artificial prostheses. These procedures are considered standard in orthopedic surgery, boasting high success rates and high levels of patient satisfaction [2,3,4]. Nevertheless, the surgeries are not without risks, including perioperative complications such as infection, thrombosis, and prosthetic dislocation. Additionally, the economic burden on healthcare systems is considerable, encompassing not only the costs of the surgery itself but also postoperative care and rehabilitation. Hence, it is essential that the procedure yields the desired pain-relieving and functional outcomes to justify its use. Osteoarthritis is the primary indication for arthroplasty, representing a leading cause of disability worldwide. In advanced stages of osteoarthritis, the pain profile can become multifaceted, often involving a combination of nociceptive, neuropathic, and nociplastic pain mechanisms. Nociceptive pain, stemming from joint tissue damage and inflammation, is the most prevalent form and is usually effectively managed by arthroplasty. However, the complexity of pain perception in osteoarthritis extends beyond the joint, potentially involving altered pain processing pathways within the central and peripheral nervous systems. Up to 20% of patients report significant persistent pain following arthroplasty despite uncomplicated surgery and no apparent source of pain. This could be explained by the presence of non-nociceptive pain. Neuropathic pain stem from nerve damage, while nociplastic pain is associated with altered central pain processing, leading to pain persisting even after the natural healing process [5]. Identifying the type of pain in patients with persistent post-surgical pain could have important implications for pre-surgical as well as post-surgical management.
Objective: The aim of this study is to explore the pain composition in terms of neuropathic, nociceptive and nociplastic pain in patients with persistent pain after total knee arthroplasty (TKA), total hip arthroplasty (THA), or unicompartmental knee arthroplasty (UKA).
Hypotheses: The investigators hypothesize that postoperative pain with multiple pain types is prevalent and that neuropathic and nociplastic pain is co-existent or conflated in a considerable proportion of patients. Thus, there is an increased prevalence of potential nociplastic pain among patients with a Neuropathic Pain score (DN4) reflecting 'possible neuropathic pain'.
Perspective: Correct identification of pain types has important implications for pain management pre-operatively, peri-operatively, and post-operatively. Moreover, a high proportion of patients with potential nociplastic pain could increase the focus on the link between preoperative patient characteristics and post-operative potential nociplastic pain. This would help targeting those individuals benefiting most from operation compared to non-surgical management. Although results from this post-operative population do not necessarily reflect the prevailing pre-operative pain composition, the results from the study can potentially form the basis for hypothesis testing in a pre-operative cohort.
Methods This protocol was registered before initiation of data collection.
Study design Descriptive Cohort Study: Approximately 7,000 patients have been administered questionnaires to indicate persistent postoperative pain including the DN4 questionnaire to indicate potential neuropathic pain [6]. All patients with evidence of persistent pain following operation and have consented to be contacted, will receive invitation to participate in the study to complete new patient-reported outcome measures (PROMs). For comparison in pain composition between patients with and without possible neuropathic pain, the investigators expect to include 100 patients with possible neuropathic pain, as around 6% of the 7,000 (with 25% consenting to be contacted) scored high enough to consider possible neuropathic pain.
Variables The DN4 will be administered again to assess any development. Nociplastic pain will be evaluated based on the International Association for the Study of Pain (IASP) criteria and using the Fibromyalgia Survey Questionnaire (FSQ), and nociceptive pain will be measured through Knee injury and Osteoarthritis Outcome Pain Domain Score (KOOS) / Hip Disability and Osteoarthritis Outcome Score (HOOS). Patients will also be asked about their satisfaction with the outcome and their thoughts on potential re-operation.
Outcomes
Secondary outcomes:
Inclusion and exclusion criteria:
Inclusion criteria: All patients with persistent moderate-severe pain (NRS>3) after THA, TKA and UKA and acceptance to be contacted.
Exclusion criteria: Re-operation or luxation, do not want to be contacted, post-operative complications such as prosthesis infection, thromboembolism or fracture of the prosthesis.
Questionnaires
The questionnaire is a combination of following questionnaires (Appendix A):
Statistical considerations
Descriptive cohort study. As such, no formal power calculation is conducted and the sample size depends on response rate form an pre-defined cohort. All statistical analyses will be conducted by using R statistical software version 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria). within RStudio (version 1.4.1717). A two-tailed P \< 0.05 will be considered statistically significant. Data will be reported as mean (standard deviation (SD)) and mean difference (95% confidence interval (95% CI): lower limit (LL), upper limit (UL)).
References:
Descriptive Cohort Study: Approximately 7,000 patients have been administered questionnaires to indicate persistent postoperative pain including the DN4 questionnaire to indicate potential neuropathic pain [6]. All patients with evidence of persistent pain following operation and have consented to be contacted, will receive invitation to participate in the study to complete new patient-reported outcome measures (PROMs). For comparison in pain composition between patients with and without possible neuropathic pain, we expect to include 100 patients with possible neuropathic pain, as around 6% of the 7,000 (with 25% consenting to be contacted) scored high enough to consider possible neuropathic pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Explore the pain composition in terms of neuropathic, nociceptive and nociplastic pain in patients with persistent pain after total knee arthroplasty (TKA), total hip arthroplasty (THA), or unicompartmental knee arthroplasty (UKA).
Potential nociplastic pain
Prevalence of potential nociplastic pain (defined by International Association for the Study of Pain criteria)
Time frame: 1 year
Difference between baseline and re-evaluated neuropathic pain score.
Difference between baseline and re-evaluated neuropathic pain score.
Time frame: 1 year
Prevalence of potential nociplastic pain, as assessed with the Fibromyalgia Survey Questionnaire score.
Prevalence of potential nociplastic pain, as assessed with the Fibromyalgia Survey Questionnaire score.
Time frame: 1 year
Distribution of Knee injury and Osteoarthritis Outcome Score (KOOS)
Distribution of Knee injury and Osteoarthritis Outcome Score (KOOS)
Time frame: 1 year
Distribution of Hip injury and Osteoarthritis Outcome Score (HOOS)
Distribution of Hip injury and Osteoarthritis Outcome Score (HOOS)
Time frame: 1 year
Difference in pain distribution in terms of International Association for the Study of Pain score in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).
Difference in pain distribution in terms of International Association for the Study of Pain score in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).
Time frame: 1 year
Rates of satisfaction
Rates of satisfaction
Time frame: 1 year
Rates of consideration of re-operation.
Rates of consideration of re-operation.
Time frame: 1 year
Difference in pain distribution in terms of Fibromyalgia Survey Questionnaire score in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).
Difference in pain distribution in terms of Fibromyalgia Survey Questionnaire score in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).
Time frame: 1 year
Difference in pain distribution in terms of Knee injury and Osteoarthritis Outcome Score (KOOS) in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).
Difference in pain distribution in terms of Knee injury and Osteoarthritis Outcome Score (KOOS) in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).
Time frame: 1 year
Difference in pain distribution in terms of Hip injury and Osteoarthritis Outcome Score (HOOS) in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).
Difference in pain distribution in terms of Hip injury and Osteoarthritis Outcome Score (HOOS) in patients with possible neuropathic pain (neuropathic pain score above 3) and patients without any kind of neuropathic pain (score equal to zero).
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 505 non-industry observational studies under Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 17 months is below that.
Counting every sponsor, half of 520 studies reached it within 18 months; a quarter within 8 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.